Profile data is unavailable for this security.
About the company
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company operates through the Pharmaceuticals segment. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. It offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The Company has manufacturing plants at Baddi, Himachal Pradesh. The Company manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
- Revenue in INR (TTM)817.15m
- Net income in INR-175.35m
- Incorporated2002
- Employees293.00
- LocationBrooks Laboratories Ltd502 Andheri, Andheri Kurla RoadMUMBAI 400093IndiaIND
- Phone+91 2 261933100
- Fax+91 2 261933114
- Websitehttps://www.brookslabs.net/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Par Drugs and Chemicals Ltd | 953.11m | 145.67m | 3.00bn | 105.00 | 20.60 | -- | 16.59 | 3.15 | 11.83 | 11.83 | 77.42 | -- | -- | -- | -- | -- | -- | 13.52 | -- | 16.46 | 66.84 | 50.26 | 15.28 | 13.42 | -- | 174.25 | -- | -- | -0.1132 | 15.60 | 27.94 | 42.01 | 77.72 | -- |
Brooks Laboratories Ltd | 817.15m | -175.35m | 3.87bn | 293.00 | -- | -- | -- | 4.74 | -6.84 | -6.84 | 31.86 | -- | -- | -- | -- | 2,788,911.00 | -- | -13.86 | -- | -22.90 | 29.09 | 26.19 | -21.46 | -27.47 | -- | 0.0861 | -- | -- | 25.76 | 7.63 | 6.26 | -- | -12.73 | -- |
Medico Remedies Ltd | 1.44bn | 85.50m | 3.93bn | 193.00 | 46.66 | -- | 34.30 | 2.73 | 1.02 | 1.02 | 17.15 | -- | -- | -- | -- | 7,474,037.00 | -- | 6.15 | -- | 12.40 | 25.07 | 25.26 | 5.93 | 3.99 | -- | 12.49 | -- | -- | 3.19 | 8.21 | 14.49 | 39.49 | -7.58 | -- |
SMS Lifesciences India Ltd | 3.24bn | 178.73m | 4.49bn | 574.00 | 25.13 | -- | 13.95 | 1.39 | 59.10 | 59.10 | 1,070.58 | -- | -- | -- | -- | 5,642,058.00 | -- | 4.08 | -- | 6.73 | 34.82 | 29.68 | 5.33 | 4.46 | -- | 2.88 | -- | 2.61 | -3.04 | -4.13 | -20.68 | -12.62 | -3.09 | 0.00 |
Venus Remedies Ltd. | 6.15bn | 285.31m | 4.57bn | 1.19k | 16.01 | -- | 8.56 | 0.7437 | 21.37 | 21.37 | 461.21 | -- | -- | -- | -- | 5,180,368.00 | -- | 4.82 | -- | 6.17 | 40.74 | 38.90 | 4.64 | 5.58 | -- | 662.71 | -- | -- | 8.27 | 13.32 | 7.25 | -- | 6.38 | -- |
Holder | Shares | % Held |
---|---|---|
quant Money Managers Ltd.as of 30 Aug 2024 | 1.01m | 3.86% |